Ayala Pharmaceuticals, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Ayala Pharmaceuticals, Inc. | AYLA - NASDAQ |
$14.00-$16.00 | $15.00 | $15.66 | 3.7 million | 5/8/2020 |
| Citigroup, Jefferies | ||||||
Co-Manager(s): Oppenheimer, Raymond James | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-03-06 Terms Added 2020-05-04 | ||||||
Ayala Pharmaceuticals, Inc. Quote & Chart - Click for current quote - AYLA
IPO Boutique aggregates information on public companies and private companies, such as "AYLA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Ayala Pharmaceuticals, Inc. (adapted from Ayala Pharmaceuticals, Inc. prospectus):
They are a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Our differentiated development approach is predicated on identifying and addressing tumorigenic drivers of cancer, through a combination of our bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Our differentiated development approach is predicated on identifying and addressing tumorigenic drivers of cancer, through a combination of our bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "AYLA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.